Theralink Technologies (OTC: THER) announced a dedicated Proprietary Laboratory Analyses (PLA) code, 0249U, for its Theralink Assay for Advanced Breast Cancer. This assay measures activated protein levels, aiding oncologists in therapy selection. The company plans to bill using this new code, which may enhance its financial prospects. Additionally, Theralink is working with Medicare Administrative Contractors to establish an appropriate reimbursement rate for the Theralink test. This milestone reinforces Theralink's position as a leader in precision medicine for oncology.
Theralink Technologies (OTC: THER) announced early results of its CLIA assay for breast cancer, revealing over 90% actionability across subtypes. Analyzed from 118 patients, findings suggest oncologists change treatment plans 78% of the time using the assay. The company's patented phosphoprotein assay offers insights beyond traditional NGS tests, which typically have a 1-10% actionable rate. CEO Mick Ruxin expressed optimism about the data aiding reimbursement initiatives. Further studies and data publications are planned for 2022-2023.
Theralink Technologies has received approval for a name and ticker symbol change from 'OBMP' to 'THER,' effective February 25, 2022, as announced by FINRA. The company can now resume issuing shares of its common stock, which had been temporarily suspended. President & CEO Mick Ruxin expressed excitement about future business initiatives aimed at reducing cancer patient morbidity and mortality. Theralink Technologies specializes in precision medicine and proteomics, focusing on molecular profiling to support drug development and improve cancer outcomes.